Financials
Financial year 2025
LN PHARMA CONSULTING from Seraing, company number BE0751561740, closed financial year 2025 with a result of € 52,325 after tax. For that financial year LN PHARMA CONSULTING recorded a gross margin of € 62,661 and equity of € 11,501. Compared with financial year 2024, the result moved from € 49,328 to € 52,325. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 11,501
▲ 25% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 52,325
▲ 6% vs 2024
Profit after tax over the fiscal year.
€ 36,597
▲ 140% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 50,000 paid out
96 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 1,242
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 614
▼ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 82,117
▲ 6% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -2,089 | € 31,964 | € 64,013 | € 62,661 | ▼ 2% |
| Profit after taxes | € -6,010 | € 25,855 | € 49,328 | € 52,325 | ▲ 6% |
| Equity | € 18,993 | € 9,848 | € 9,176 | € 11,501 | ▲ 25% |
| Total debts | € 935 | € 42,969 | € 78,394 | € 82,731 | ▲ 6% |
| Cash | € 1,041 | € 10,082 | € 15,236 | € 36,597 | ▲ 140% |
| Retained profit | € 13,993 | € 4,848 | € 4,176 | € 6,501 | ▲ 56% |
| Dividend | € 0 | € 35,000 | € 50,000 | € 50,000 | |
| Balance sheet total | € 19,929 | € 52,816 | € 87,569 | € 94,232 | ▲ 8% |
By gross margin, LN PHARMA CONSULTING ranks 292nd of 348 companies with main activity “Detailhandel in farmaceutische producten” in the province of Liège that publish figures (fiscal year 2025).
Key figures of LN PHARMA CONSULTING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about LN PHARMA CONSULTING the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to LN PHARMA CONSULTING?
What happened at LN PHARMA CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 52,325 (▲ 6% vs 2024). filed late Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Seraing. KBO
In short
From € 6,010 loss in 2022 to € 52,325 profit in 2025.
Paid € 36,580 in corporate taxes since 2022.
Best year ever: 2025, with € 52,325 profit.
Paid out € 135,000 in dividends to the owners in total.
Establishments
Establishment units
Physical locations of this company
Rue Toute-Voie 12
4101 Seraing
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in the province of Liège
Same main activity (Detailhandel in farmaceutische producten), 392 active companies in the province of Liège, largest first.
PHARMACIES POPULAIRES DE VERVIERS ET ARRONDISSEMENT
€ 109.5 million revenue · 2025 · Thimister-Clermont
LES PHARMACIES DU PEUPLE - Réseau Solidaris
€ 44.8 million revenue · 2025 · Seraing
€ 19.4 million revenue · 2025 · Bütgenbach
€ 17.9 million revenue · 2025 · Thimister-Clermont
Pharmacie populaire La Sauvegarde
€ 17.8 million revenue · 2025 · Soumagne
€ 12.4 million revenue · 2025 · Faimes
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- NZEYIMANA Lazare(Fondateur) 100%
Details
- Company number
- 0751.561.740
- VAT number
- BE 0751.561.740
- Registered office
- Rue Toute-Voie 12, 4101 Seraing
- Names & denominations
- LN PHARMA CONSULTING
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 July 2020
- Peppol
- Active · Active since 28 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Adviesbureaus op het gebied van public relations en communicatie